Imatinib Drugs-EMEA Market Status and Trend Report 2013-2023
Report Summary
Imatinib Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Imatinib Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Imatinib Drugs 2013-2017, and development forecast 2018-2023
Main market players of Imatinib Drugs in EMEA, with company and product introduction, position in the Imatinib Drugs market
Market status and development trend of Imatinib Drugs by types and applications
Cost and profit status of Imatinib Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Imatinib Drugs market as:
EMEA Imatinib Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Imatinib Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Capsules
Tablets
EMEA Imatinib Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Drug Stores
Other
EMEA Imatinib Drugs Market: Players Segment Analysis (Company and Product introduction, Imatinib Drugs Sales Volume, Revenue, Price and Gross Margin):
Apotex Inc.
Novartis
Sanofi S.A.
Cipla Inc.
Mylan Pharms Inc.
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Imatinib Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Imatinib Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Imatinib Drugs 2013-2017, and development forecast 2018-2023
Main market players of Imatinib Drugs in EMEA, with company and product introduction, position in the Imatinib Drugs market
Market status and development trend of Imatinib Drugs by types and applications
Cost and profit status of Imatinib Drugs, and marketing status
Market growth drivers and challenges
The report segments the EMEA Imatinib Drugs market as:
EMEA Imatinib Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Imatinib Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Capsules
Tablets
EMEA Imatinib Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Drug Stores
Other
EMEA Imatinib Drugs Market: Players Segment Analysis (Company and Product introduction, Imatinib Drugs Sales Volume, Revenue, Price and Gross Margin):
Apotex Inc.
Novartis
Sanofi S.A.
Cipla Inc.
Mylan Pharms Inc.
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF IMATINIB DRUGS
1.1 Definition of Imatinib Drugs in This Report
1.2 Commercial Types of Imatinib Drugs
1.2.1 Capsules
1.2.2 Tablets
1.3 Downstream Application of Imatinib Drugs
1.3.1 Hospitals
1.3.2 Drug Stores
1.3.3 Other
1.4 Development History of Imatinib Drugs
1.5 Market Status and Trend of Imatinib Drugs 2013-2023
1.5.1 EMEA Imatinib Drugs Market Status and Trend 2013-2023
1.5.2 Regional Imatinib Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Imatinib Drugs in EMEA 2013-2017
2.2 Consumption Market of Imatinib Drugs in EMEA by Regions
2.2.1 Consumption Volume of Imatinib Drugs in EMEA by Regions
2.2.2 Revenue of Imatinib Drugs in EMEA by Regions
2.3 Market Analysis of Imatinib Drugs in EMEA by Regions
2.3.1 Market Analysis of Imatinib Drugs in Europe 2013-2017
2.3.2 Market Analysis of Imatinib Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Imatinib Drugs in Africa 2013-2017
2.4 Market Development Forecast of Imatinib Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Imatinib Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Imatinib Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Imatinib Drugs in EMEA by Types
3.1.2 Revenue of Imatinib Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Imatinib Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Imatinib Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Imatinib Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Imatinib Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Imatinib Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Imatinib Drugs by Downstream Industry in Africa
4.3 Market Forecast of Imatinib Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMATINIB DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Imatinib Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 IMATINIB DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Imatinib Drugs in EMEA by Major Players
6.2 Revenue of Imatinib Drugs in EMEA by Major Players
6.3 Basic Information of Imatinib Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Imatinib Drugs Major Players
6.3.2 Employees and Revenue Level of Imatinib Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IMATINIB DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Apotex Inc.
7.1.1 Company profile
7.1.2 Representative Imatinib Drugs Product
7.1.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Apotex Inc.
7.2 Novartis
7.2.1 Company profile
7.2.2 Representative Imatinib Drugs Product
7.2.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.3 Sanofi S.A.
7.3.1 Company profile
7.3.2 Representative Imatinib Drugs Product
7.3.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
7.4 Cipla Inc.
7.4.1 Company profile
7.4.2 Representative Imatinib Drugs Product
7.4.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Cipla Inc.
7.5 Mylan Pharms Inc.
7.5.1 Company profile
7.5.2 Representative Imatinib Drugs Product
7.5.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Mylan Pharms Inc.
7.6 Glenmark Pharmaceuticals Ltd.
7.6.1 Company profile
7.6.2 Representative Imatinib Drugs Product
7.6.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Glenmark Pharmaceuticals Ltd.
7.7 Sun Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Imatinib Drugs Product
7.7.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sun Pharmaceuticals
7.8 Actavis Generics
7.8.1 Company profile
7.8.2 Representative Imatinib Drugs Product
7.8.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Actavis Generics
7.9 Dr. Reddy's Laboratories
7.9.1 Company profile
7.9.2 Representative Imatinib Drugs Product
7.9.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories
7.10 Teva Pharmaceutical Industries Ltd.
7.10.1 Company profile
7.10.2 Representative Imatinib Drugs Product
7.10.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMATINIB DRUGS
8.1 Industry Chain of Imatinib Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMATINIB DRUGS
9.1 Cost Structure Analysis of Imatinib Drugs
9.2 Raw Materials Cost Analysis of Imatinib Drugs
9.3 Labor Cost Analysis of Imatinib Drugs
9.4 Manufacturing Expenses Analysis of Imatinib Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF IMATINIB DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Imatinib Drugs in This Report
1.2 Commercial Types of Imatinib Drugs
1.2.1 Capsules
1.2.2 Tablets
1.3 Downstream Application of Imatinib Drugs
1.3.1 Hospitals
1.3.2 Drug Stores
1.3.3 Other
1.4 Development History of Imatinib Drugs
1.5 Market Status and Trend of Imatinib Drugs 2013-2023
1.5.1 EMEA Imatinib Drugs Market Status and Trend 2013-2023
1.5.2 Regional Imatinib Drugs Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Imatinib Drugs in EMEA 2013-2017
2.2 Consumption Market of Imatinib Drugs in EMEA by Regions
2.2.1 Consumption Volume of Imatinib Drugs in EMEA by Regions
2.2.2 Revenue of Imatinib Drugs in EMEA by Regions
2.3 Market Analysis of Imatinib Drugs in EMEA by Regions
2.3.1 Market Analysis of Imatinib Drugs in Europe 2013-2017
2.3.2 Market Analysis of Imatinib Drugs in Middle East 2013-2017
2.3.3 Market Analysis of Imatinib Drugs in Africa 2013-2017
2.4 Market Development Forecast of Imatinib Drugs in EMEA 2018-2023
2.4.1 Market Development Forecast of Imatinib Drugs in EMEA 2018-2023
2.4.2 Market Development Forecast of Imatinib Drugs by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Imatinib Drugs in EMEA by Types
3.1.2 Revenue of Imatinib Drugs in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Imatinib Drugs in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Imatinib Drugs in EMEA by Downstream Industry
4.2 Demand Volume of Imatinib Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Imatinib Drugs by Downstream Industry in Europe
4.2.2 Demand Volume of Imatinib Drugs by Downstream Industry in Middle East
4.2.3 Demand Volume of Imatinib Drugs by Downstream Industry in Africa
4.3 Market Forecast of Imatinib Drugs in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMATINIB DRUGS
5.1 EMEA Economy Situation and Trend Overview
5.2 Imatinib Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 IMATINIB DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Imatinib Drugs in EMEA by Major Players
6.2 Revenue of Imatinib Drugs in EMEA by Major Players
6.3 Basic Information of Imatinib Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Imatinib Drugs Major Players
6.3.2 Employees and Revenue Level of Imatinib Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 IMATINIB DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Apotex Inc.
7.1.1 Company profile
7.1.2 Representative Imatinib Drugs Product
7.1.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Apotex Inc.
7.2 Novartis
7.2.1 Company profile
7.2.2 Representative Imatinib Drugs Product
7.2.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.3 Sanofi S.A.
7.3.1 Company profile
7.3.2 Representative Imatinib Drugs Product
7.3.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
7.4 Cipla Inc.
7.4.1 Company profile
7.4.2 Representative Imatinib Drugs Product
7.4.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Cipla Inc.
7.5 Mylan Pharms Inc.
7.5.1 Company profile
7.5.2 Representative Imatinib Drugs Product
7.5.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Mylan Pharms Inc.
7.6 Glenmark Pharmaceuticals Ltd.
7.6.1 Company profile
7.6.2 Representative Imatinib Drugs Product
7.6.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Glenmark Pharmaceuticals Ltd.
7.7 Sun Pharmaceuticals
7.7.1 Company profile
7.7.2 Representative Imatinib Drugs Product
7.7.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sun Pharmaceuticals
7.8 Actavis Generics
7.8.1 Company profile
7.8.2 Representative Imatinib Drugs Product
7.8.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Actavis Generics
7.9 Dr. Reddy's Laboratories
7.9.1 Company profile
7.9.2 Representative Imatinib Drugs Product
7.9.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories
7.10 Teva Pharmaceutical Industries Ltd.
7.10.1 Company profile
7.10.2 Representative Imatinib Drugs Product
7.10.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMATINIB DRUGS
8.1 Industry Chain of Imatinib Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMATINIB DRUGS
9.1 Cost Structure Analysis of Imatinib Drugs
9.2 Raw Materials Cost Analysis of Imatinib Drugs
9.3 Labor Cost Analysis of Imatinib Drugs
9.4 Manufacturing Expenses Analysis of Imatinib Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF IMATINIB DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
